Biosimilar policy has been taking shape quickly over the last few years. From Medicare Part B and D policy changes to the HHS’ elimination of Safe Harbor rebate protections, biosimilars have become a prominent topic of discussion to build a more competitive, sustainable biologics market. However, there is still much further policy development needed to realize the goal of lower healthcare costs via biosimilar utilization.
This webinar will examine the following:
- A look at the biosimilar pipeline: what has been approved and what's the next blockbuster?
- What biosimilar policies are currently being proposed, revamped, or implemented?
- How are Congressional and state policymakers planning to use biosimilars?
- How will the HHS rebate rule and CMS’ International Pricing Index play into this debate?